This site is intended for healthcare professionals

EU approves Amvuttra for hereditary transthyretin-mediated (hATTR) amyloidosis

Read time: 1 mins
Published:22nd Sep 2022

Alnylam Pharmaceuticals announced that the European Commission (EC) has granted marketing authorization for Amvuttra (vutrisiran), an RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy

The EC approval is based on positive 18-month results from the HELIOS-A Phase III study, where Amvuttra significantly improved the signs and symptoms of hATTR amyloidosis, with more than 50 percent of patients experiencing halting or reversal of their polyneuropathy manifestations.

In the HELIOS-A study, Amvuttra met the primary and all secondary endpoints of the study at both 9 months and 18 months, demonstrating reversal in neuropathy impairment and an encouraging safety and tolerability profile. Amvuttra demonstrated improvement in the mean change from baseline in modified Neuropathy Impairment Score + 7 (mNIS+7) at 18 months (the primary endpoint for the EU), as compared to external placebo data from the landmark APOLLO Phase III study of patisiran.

After 18 months of dosing, the most frequently occurring adverse reactions in Amvuttra-treated patients were arthralgia (joint stiffness) and pain in extremity (pain in arms and legs). Other less frequent adverse reactions reported with Amvuttra were dyspnea (shortness of breath), injection site reaction and an increase in blood alkaline phosphatase (a liver enzyme).

Condition: Transthyretin Amyloid Polyneuropathy
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.